This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
by Zacks Equity Research
AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.
Should iShares Core S&P Mid-Cap ETF (IJH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJH
ALNY Down Despite Positive Data From Heart Disease Drug Study
by Zacks Equity Research
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication
by Zacks Equity Research
The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.
Should iShares S&P Mid-Cap 400 Value ETF (IJJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJJ
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
by Zacks Equity Research
The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.
SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.
The Zacks Analyst Blog Highlights DaVita and Illumina
by Zacks Equity Research
DaVita and Illumina are included in this Analyst Blog.
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
by Zacks Equity Research
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx
by Zacks Equity Research
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
by Zacks Equity Research
Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.
2 Must-Buy Medical Stocks With Strong Momentum
by Nalak Das
Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
by Zacks Equity Research
OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
Top Stock Picks for Week of August 26, 2024
by Panel Of Zacks Experts
A Tech Stock with Growing Dominance in the Thermal Management Space and a Life Sciences Company with a Strong Pipeline.
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
by Zacks Equity Research
The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
by Zacks Equity Research
The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
Amicus (FOLD) Banks on Galafold, High Dependence a Concern
by Zacks Equity Research
Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
by Zacks Equity Research
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition
by Zacks Equity Research
Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The deal is likely to strengthen the company's MedTech business unit further.
GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.